NextFin News - CVC Capital Partners is exploring a bid to take Verisure plc private, barely 12 months after the home-security group's landmark €3.2 billion Stockholm listing, according to people familiar with the matter. The timing is no accident: Hellman & Friedman's 365-day lock-up on its majority stake expires in early October 2026, opening the door for the US private equity firm to exit - and for CVC to buy a category leader at a discount that public markets created, not the business.
Verisure shares closed at €9.36 in Stockholm on October 21, 2026, giving the company a market capitalization of roughly €9.5 billion - about 29% below the €13.25 per share at which it listed on October 8, 2025, and less than 60% of the €16.52 peak the stock touched in its first week of trading. For CVC, Europe's largest independent private equity house, the gap between a compounding subscription business and a punished share price is the classic buyout setup. For Hellman & Friedman, it is a test of the public-market future it championed only a year ago.
The Deal That Would Rewrite the IPO Narrative
Verisure's flotation was billed as the moment Europe's IPO market came back to life. It was the region's biggest listing since 2022 and Sweden's largest since 2000, raising €3.2 billion at €13.25 a share and valuing the company at €13.7 billion. Shares jumped 21% on their debut and closed at €16, handing early investors a paper gain and giving sponsors across the continent a template: list your best asset, wait for the re-rating, sell into strength.
The template broke. The stock spent the following year in a €7.70-€16.52 range, and investors who bought the offering remain underwater even after the shares recovered from their lows earlier in 2026. A take-private at a meaningful premium to €9.36 would hand CVC an asset with €3.6 billion of annualised recurring revenue, nearly 6.4 million customers across 18 countries, and a subscription model that generates cash through economic cycles. It would hand Hellman & Friedman something equally valuable: a face-saving exit from a public market that has refused to re-rate the shares despite the company hitting every guidance marker it set at the IPO.
This would not be CVC's first large European take-private of the year. The firm, alongside Belgian investment group GBL, launched a €10.7 billion full cash bid for Italian drugmaker Recordati and later sweetened the offer to €53 per share after an activist investor argued the initial price undervalued the company. That deal shows CVC's appetite, its willingness to pay up for defensive cash flows, and its comfort with the complex shareholder negotiations a Verisure transaction would require.
Why Verisure, and Why Now
Beneath the share price, the business is performing exactly as promised. In the first half of 2026, revenue rose 10.6% year on year to €2,043.0 million. Annualised recurring revenue grew 12.2% to €3,619.8 million. Adjusted EBITDA climbed 11.3% to €939.9 million, and adjusted EBIT rose 13.9% to €268.8 million with margin expanding 83 basis points to 26.3%. Total customers reached approximately 6.4 million, up 9.4% from a year earlier, and the company added 441,499 new subscribers in the period.
The balance sheet is already buyout-ready. Net debt stood at €4.9 billion at the end of June 2026, with last-twelve-months net leverage at 2.7 times EBITDA - inside the company's stated target range of 2.5-2.75 times by the end of 2026. In late October 2025, Verisure completed a post-IPO refinancing program that included a new seven-year €1.25 billion term loan B priced at Euribor plus 225 basis points, a structure that gives a future owner predictable debt terms and a clear path to the leverage levels private equity sponsors typically target.
The disconnect between operating performance and share price is precisely what attracts buyout capital. CVC's calculus runs like this: the public market is pricing Verisure as a slow-growth utility, while the company is still compounding ARR at double-digit rates, expanding margins, and generating positive free cash flow - the group reported €56.2 million of free cash flow in the second quarter of 2026, a sharp swing from negative €41.1 million a year earlier. With interest expense set to fall by €200-220 million annually following the refinancing, a private owner captures the full benefit of that deleveraging without sharing it with public shareholders.
"Under Austin and his team's leadership, Verisure has gone from strength to strength, with a long record of organic growth, margin expansion and strong cash generation. As Verisure transitions to the public markets, we see significant opportunity ahead and look forward to continuing to support Verisure as committed, long-term shareholders."
That was Stefan Goetz, chairman of Verisure's board and a partner at Hellman & Friedman, at the IPO. CEO Austin Lally, for his part, has repeatedly framed the listing as the start of a long public-market chapter, not a prelude to an exit. One year later, both men's words are being tested by a sponsor that sees the same cash flows and a much cheaper entry price.
The Mechanics of a Take-Private
Any offer faces structural hurdles that make this harder than a standard buyout. Hellman & Friedman retains a majority stake, so CVC would need the controlling shareholder's cooperation - and a price that compensates H&F for abandoning a public listing it only just engineered. A deal would also require financing in a debt market that has only recently reopened for large leveraged buyouts, at spreads that are still well above the levels that made 2021's mega-deals economic.
The arithmetic is unforgiving. At €9.36 per share, Verisure's equity is worth roughly €9.5 billion. Adding €4.9 billion of net debt implies an enterprise value near €14.4 billion - essentially the IPO valuation, but for a business that has since grown ARR by more than 10% and EBITDA by more than 11%. A typical buyout premium of 30-40% would push the equity value toward €12.4-13.3 billion and enterprise value toward €17-18 billion, or roughly 13-14 times trailing adjusted EBITDA. That is rich for European leveraged finance, where deals above 12 times EBITDA have been rare since the rate shock of 2022-2023. It is not, however, unheard of for a defensive, recurring-revenue asset with the customer retention profile Verisure claims.
The most likely structure is not a hostile bid but a consortium. CVC would probably invite H&F to roll part of its stake into the new vehicle, sharing the upside of a future re-listing or sale while giving CVC control and giving H&F the liquidity it needs. That mirrors the structure CVC used with Recordati, where it partnered with GBL and had to negotiate with a large existing shareholder base. The alternative - a full cash offer that squeezes out H&F - would damage CVC's relationship with one of the world's most influential buyout firms, a cost no sponsor willingly pays.
Is This Cyclical Weakness or a Structural Repricing?
The central question for any bidder is whether Verisure's share-price discount reflects a cyclical dip that will mean-revert, or a structural repricing that will persist. Getting this wrong flips the conclusion: if the discount is cyclical, today's price is a gift; if it is structural, a 30% premium is still too much.
Three signals support the cyclical read. First, the fundamentals have not broken. ARR growth of 12.2%, EBITDA growth of 11.3%, and leverage already at target are not the profile of a deteriorating business - they are the profile of a company executing a plan while its multiple compresses. Second, the stock's decline tracks the broader European IPO hangover of 2025-2026, when newly listed companies were re-rated lower as rate expectations shifted and IPO demand faded - a market-wide phenomenon, not a company-specific one. Third, Verisure's revenue is contractually recurring; the cash flows do not disappear because the multiple compresses, which means the equity is mispriced rather than the business impaired.
But a structural argument exists, and it is the one CVC's investment committee will press hardest. European private equity exit windows have narrowed structurally, not cyclically. Regulatory scrutiny of leveraged deals has increased, pension-fund allocations to private equity have peaked, and IPO investors burned on 2025 debuts may demand a permanently higher risk premium for new listings - compressing the terminal multiple any buyer can underwrite. If public markets permanently assign a lower multiple to monitored-security businesses, today's discount is not a bargain; it is the new fair value, and a take-private at a premium simply transfers value from the buyer to H&F.
Our judgment: cyclical, with a structural caveat. The multiple compression is a market phenomenon that will revert as rate cuts feed through to equity valuations and as Verisure's dividend - initiated in September 2026 - builds an income-investor base that anchors the share price. But the reversion may take longer than a typical five-to-seven-year private equity hold period allows, which is why CVC would need to pay carefully and why a consortium structure with H&F rolling equity is more likely than a clean buyout.
The Second-Order Consequence Nobody Is Discussing
The obvious read is that a CVC bid validates Verisure's business model. The less obvious one is what it signals about the European IPO market itself - and about the private equity industry's relationship with public markets.
If a company that delivered on its guidance, cut leverage to target, initiated a dividend, and still trades 29% below its offer price can only find a buyer in a private equity sponsor, then the public market has failed as a price-discovery mechanism for growth assets. That failure has a chilling second-order effect. Other private equity owners sitting on European assets - some of which delayed IPOs in 2025-2026 and are now watching Verisure closely - will take note of how H&F is treated. If H&F accepts a take-private at a modest premium, sponsors will conclude that the IPO route is a trapdoor: you can list, but you cannot exit. The result would be a shift back toward secondary sales and take-privates, starving European exchanges of the quality listings they need to rebuild market depth.
There is a darker variant. Verisure's IPO was structured so that H&F did not sell shares in the main offering; instead, it raised cash through a special-purpose vehicle sitting outside Verisure's balance sheet - a sophisticated way to monetise while keeping control. If that structure now funnels toward a take-private just 12 months after admission, retail and institutional investors who bought the flotation may conclude that sponsor-aligned IPOs are designed to fail upward: the sponsor wins either way, and the public shareholder funds the option. That perception, once formed, is hard to undo.
Conversely, if H&F rejects the approach and Verisure's shares recover toward their IPO price on the strength of continued execution, the IPO channel reopens - and the 2025 vintage gets its vindication. The next few weeks will tell which path Europe's public markets are on.
The Counter-Case: Why CVC Might Walk Away
The strongest argument against a deal is the price, and it is a hard one. Verisure is not cheap on an enterprise-value basis once debt is included, and European leveraged-loan spreads remain elevated relative to the 2021 peak. A bid at €12-13 per share would require debt markets to cooperate at a time when covenant-lite issuance is only just returning. If financing costs rise by even 100-150 basis points, the arbitrage between the public price and the private value evaporates - and CVC, which has been disciplined about entry multiples, walks.
There is also the H&F problem. Hellman & Friedman is not a typical seller. It held Verisure for 15 years, built it into a category leader, and chose a public listing over a trade sale precisely because it believed the public market would pay more over time than any single buyer. Rebuffing CVC would be consistent with that conviction - and with H&F's reputation as a firm that does not sell assets under pressure. Forcing a sale would damage CVC's relationship with one of the most influential firms in private equity; partnering with H&F would require splitting economics in a way that satisfies a sponsor that has shown little urgency to exit.
The falsifying signal is concrete and near-term: if Verisure's third-quarter results, due November 3, 2026, show ARR growth slowing below 8% year on year, or adjusted EBITDA margin contracting by more than 100 basis points, the cyclical thesis breaks. At that point the share-price discount becomes fundamental - a reflection of deteriorating unit economics rather than market sentiment - and a take-private at any reasonable premium becomes uneconomic. A second falsifying signal sits in the debt market: if European leveraged-loan spreads widen by more than 50 basis points over the coming quarter, the financing math fails regardless of Verisure's operating performance.
What To Watch
- Hellman & Friedman's response. As majority holder with a freshly expired lock-up, H&F holds the keys. A flat "no comment" buys time and keeps shares range-bound; a rejection sends them back toward €9; an announcement of engagement lifts the stock toward deal math.
- Q3 2026 results, due November 3, 2026. The next proof point on ARR growth, margin trajectory, and free cash flow - the three metrics that determine whether this is a growth story at a value price or a value trap at a growth multiple.
- European leveraged-finance conditions. A take-private of this size needs €10 billion-plus of financing. If loan spreads widen or covenant terms tighten, the deal window closes regardless of strategic logic.
- The dividend trail. Verisure paid its first ordinary dividend on September 17, 2026, to shareholders of record on September 10. A growing payout builds an income-investor base that anchors the share price and caps CVC's ability to accumulate quietly - but it also proves the cash-generation story that underpins any buyout model.
- The lock-up clock. With H&F's 365-day lock-up now expired, any secondary block sale would signal the sponsor's willingness to reduce exposure - a green light for CVC. No sale, no talks, signals conviction that the public market will eventually re-rate the shares.
Scenarios
Base case: CVC tests the water with H&F but no formal offer emerges in the near term. Verisure shares trade in a €9-11 range as the market waits for Q3 results and clearer financing conditions. The takeover overhang provides a floor; the IPO overhang provides a ceiling. H&F holds, the dividend grows, and the shares grind higher on earnings rather than deal news.
Upside case: CVC and H&F agree on a consortium take-private at €12-13 per share, a 30-40% premium to the pre-news price. Verisure exits the public market 12 months after its debut, H&F books a modest gain on a business it held for 15 years, and CVC secures a defensive cash-flow asset at an entry multiple it can defend. European IPO pipelines freeze as sponsors conclude that take-privates, not listings, are the exit of choice.
Downside case: H&F rebuffs the approach, financing conditions tighten, and Verisure's shares drift back toward the €7.70 low as IPO investors capitulate. The company continues to execute operationally - ARR grows, margins expand, leverage falls - while the multiple stays compressed. The public market remains a holding pen, not an exit.
The irony is sharp: Verisure sells peace of mind to 6.4 million customers, yet its own shareholders have had anything but. CVC's interest is a vote that the business is sound and the price is wrong. Whether that vote becomes a deal depends less on Verisure's performance - which has been solid - than on whether Europe's private equity firms can still underwrite the gap between a company's cash flows and the market's patience. In the end, the Verisure story is not about alarm systems. It is about whether the European IPO market of the mid-2020s was a bridge to the public markets, or a one-year waiting room before the sponsors came back to collect.
Explore more exclusive insights at nextfin.ai.
